Zepbound vs. Saxenda

See how Zepbound and Saxenda compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Both are injectable weight-loss medicines, but Zepbound targets two gut hormones and is dosed weekly, while Saxenda targets one hormone and is injected daily.

  • Zepbound is the only one of the two FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, in addition to weight management.

  • Saxenda has been available since 2014 and is approved for adolescents 12 to 17, while Zepbound is approved only for adults 18 and older.

Zepbound vs. Saxenda Drug Summary

Zepbound

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. It works by mimicking two gut hormones that curb appetite and slow digestion. It is injected under the skin once a week, with the dose raised gradually from 2.5 mg to a maximum of 15 mg.

Saxenda

Saxenda (liraglutide) is a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and in adolescents 12 to 17 with obesity. It mimics one gut hormone to reduce appetite and slow stomach emptying. It is injected under the skin once a day, with the dose raised weekly from 0.6 mg to a maintenance dose of 3 mg.

Zepbound vs. Saxenda Side Effects

Zepbound

Most common
Nausea (up to 29%)
Diarrhea (up to 23%)
Constipation (up to 17%)
Vomiting (up to 13%)

Saxenda

Most common
Nausea (up to 39.3%)
Diarrhea (up to 20.9%)
Constipation (up to 19.4%)
Vomiting (up to 15.7%)

Zepbound vs. Saxenda Dosage

Zepbound

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mg once weekly Weeks 1-4
Maximum dose 15 mg once weekly Week 21 onward
Dose changes 5 increases Every 4 weeks

Saxenda

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 3 mg once daily Week 5 onward
Dose changes 4 increases Every week

Zepbound vs. Saxenda Indications

Zepbound

Zepbound is FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition such as high blood pressure or high cholesterol. It also carries a separate approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Both uses call for pairing the drug with a reduced-calorie diet and more physical activity.

  • Chronic weight management in adults with obesity

  • Weight management in overweight adults with a related condition

  • Moderate-to-severe obstructive sleep apnea with obesity

  • Used alongside diet and exercise changes

  • Not approved for diabetes treatment

Saxenda

Saxenda is FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It is also approved for adolescents ages 12 to 17 with obesity. Saxenda is not indicated for diabetes; a higher-dose liraglutide product for that use is sold separately as Victoza.

  • Chronic weight management in adults with obesity

  • Weight management in overweight adults with a related condition

  • Chronic weight management in adolescents ages 12-17 with obesity

  • Used alongside diet and exercise changes

  • Not approved for diabetes treatment (that's Victoza)

Zepbound vs. Saxenda Pros and Cons

Zepbound

Zepbound's dual-hormone mechanism has produced some of the largest average weight-loss results seen in GLP-1-class trials, and it is the only drug here also approved for sleep apnea. Insurance coverage has expanded but many plans still require prior authorization, and the multi-step titration means reaching the top dose can take months.

Pros

  • Dual GIP/GLP-1 action linked to greater average weight loss than GLP-1-only drugs like Saxenda

  • Only medication FDA-approved for both obesity and moderate-to-severe obstructive sleep apnea

  • Once-weekly injection instead of a daily shot

Cons

  • Newer to market with less long-term real-world data than Saxenda, available since 2014

  • Longer titration schedule, up to 20 weeks to reach the top 15 mg dose

  • Not approved for adolescents; Saxenda covers ages 12 to 17

  • Six different dose strengths can complicate refills and pharmacy stocking

Saxenda

Saxenda has over a decade of safety data as the first GLP-1 approved for weight management, plus a pediatric approval Zepbound lacks. Coverage varies by plan, and its daily injection and generally smaller average weight loss compared with dual-acting drugs are trade-offs some patients weigh against familiarity.

Pros

  • Longer track record, in use for weight management since 2014

  • Shorter titration, only 4 weeks to reach the maintenance dose

  • Approved for adolescents 12 to 17 with obesity, an age group Zepbound does not cover

Cons

  • Requires a daily injection instead of once a week

  • Single-hormone GLP-1 action tends to produce less average weight loss than dual-acting Zepbound

  • Higher list price than Zepbound, roughly $1,300 to $1,350 a month before savings programs

  • Not approved for obstructive sleep apnea

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.